Brain/Spinal Cord Cancers

 

Chemotherapy Plus Chemoprotected Autologous Stem Cells for Malignant Gliomas (FHCRC-2000)
Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells for Patients with Malignant Gliomas

Investigator: Hans-Peter Kiem, MD;   Conditions: Brain Cancer; Glioma; Solid Tumors;    Status: Recruiting;   Study ID: NCT00669669

Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors (7140)
A Phase 1 and 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

Investigator: Daniel Silbergeld;   Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor;    Status: Recruiting;   Study ID: NCT01148966

Observation/Radiation Therapy for Grade I, II, or III Meningioma
Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Researchers

Investigator: George Laramore, MD;   Conditions: Brain and Central Nervous System Tumors;    Status: Recruiting;   Study ID: NCT00895622

Radiation w/wo Temozolomide for Low-Grade Gliomas
Phase III Study of Radiation Therapy With or Without Temozolomide For Symptomatic or Progressive Low-Grade Gliomas CCIRB#7269

Investigator: George Laramore, MD;   Conditions: Brain and Central Nervous System Tumors, Neurotoxicity Syndromes;    Status: Recruiting;   Study ID: NCT00978458

MEDI-575 for Recurrent Glioblastoma Multiforme (20110231)
Phase 2 Study of MEDI-575 in Adult Subjects with Recurrent Glioblastoma Multiforme

Investigator: Marc Chamberlain, MD;   Conditions: Glioblastoma Multiforme;    Status: Recruiting;   Study ID: NCT01268566

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas (7329)
Phase II trial of bevacizumab (Avastin) in patients with recurrent or progressive meningiomas

Investigator: Marc Chamberlain, MD;   Conditions: Brain Cancer;    Status: Recruiting;   Study ID: NCT01125046

Radiation Therapy w/wo Cediranib Maleate for Newly Diagnosed Glioblastoma (7196)
Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed Glioblastoma

Investigator: George Laramore, MD;   Conditions: Brain and Central Nervous System Tumors;    Status: Temporarily Suspended;   Study ID: NCT01062425